You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 24, 2024

List of Excipients in API valsartan


✉ Email this page to a colleague

« Back to Dashboard


Excipients in NDA-approved (novel) drugs containing valsartan

Glossary
Company Tradename Ingredient NDC Excipient Potential Generic Entry
Novartis Pharmaceuticals Corporation DIOVAN valsartan 0078-0423 CELLULOSE, MICROCRYSTALLINE
Novartis Pharmaceuticals Corporation DIOVAN valsartan 0078-0423 CROSPOVIDONE
Novartis Pharmaceuticals Corporation DIOVAN valsartan 0078-0423 FERRIC OXIDE YELLOW
Novartis Pharmaceuticals Corporation DIOVAN valsartan 0078-0423 HYPROMELLOSES
Novartis Pharmaceuticals Corporation DIOVAN valsartan 0078-0423 MAGNESIUM STEARATE
>Company >Tradename >Ingredient >NDC >Excipient >Potential Generic Entry

Subscribe to access the full database, or Sign Up

Detailed excipient profiles for valsartan

Excipient focus: ANHYDROUS DIBASIC CALCIUM PHOSPHATE

Excipient focus: ANHYDROUS LACTOSE

Excipient focus: CELLULOSE, MICROCRYSTALLINE

Excipient focus: CROSCARMELLOSE SODIUM

Excipient focus: CROSPOVIDONE

Excipient focus: FD&C BLUE NO. 1

Excipient focus: FD&C BLUE NO. 2

Excipient focus: FD&C RED NO. 40

Excipient focus: FD&C YELLOW NO. 6

Excipient focus: FERRIC OXIDE RED

Excipient focus: FERRIC OXIDE YELLOW

Excipient focus: FERROSOFERRIC OXIDE

Excipient focus: HYDROXYPROPYL CELLULOSE

Excipient focus: HYDROXYPROPYL CELLULOSE, LOW SUBSTITUTED

Excipient focus: HYPROMELLOSE

Excipient focus: HYPROMELLOSE 2910

Excipient focus: HYPROMELLOSES

Excipient focus: INDIGOTINDISULFONATE SODIUM

Excipient focus: LACTOSE MONOHYDRATE

Excipient focus: LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE

Excipient focus: MAGNESIUM STEARATE

Excipient focus: MANNITOL

Excipient focus: METHYLPARABEN

Excipient focus: MICROCRYSTALLINE CELLULOSE 101

Excipient focus: MICROCRYSTALLINE CELLULOSE 102

Excipient focus: POLOXAMER 188

Excipient focus: POLYDEXTROSE

valsartan drug variants containing POLYDEXTROSE

Company Ingredient NDC
Mylan Pharmaceuticals Inc valsartan and hydrochlorothiazide 0378-6321
A-S Medication Solutions valsartan and hydrochlorothiazide 50090-5985
Northwind Pharmaceuticals LLC valsartan and hydrochlorothiazide 51655-243
Northwind Pharmaceuticals LLC valsartan and hydrochlorothiazide 51655-389
Preferred Pharmaceuticals Inc valsartan and hydrochlorothiazide 68788-7887
>Company >Ingredient >NDC

Subscribe to access the full database, or Sign Up

Excipient focus: POLYETHYLENE GLYCOL

Excipient focus: POLYETHYLENE GLYCOL 3350

Excipient focus: POLYETHYLENE GLYCOL 400

Excipient focus: POLYETHYLENE GLYCOL 4000

Excipient focus: POLYETHYLENE GLYCOL 6000

Excipient focus: POLYETHYLENE GLYCOL 8000

Excipient focus: POLYETHYLENE GLYCOLS

Excipient focus: POLYVINYL ALCOHOL

Excipient focus: POTASSIUM SORBATE

Excipient focus: POVIDONE

Excipient focus: POVIDONE K30

Excipient focus: PROPYLENE GLYCOL

Excipient focus: SILICON DIOXIDE

Excipient focus: SODIUM HYDROXIDE

Excipient focus: SODIUM LAURYL SULFATE

Excipient focus: STARCH, CORN

Excipient focus: STARCH, PREGELATINIZED CORN

Excipient focus: SUCRALOSE

Excipient focus: TALC

Excipient focus: TITANIUM DIOXIDE

Excipient focus: TRIACETIN

valsartan drug variants containing TRIACETIN

Company Ingredient NDC
Mylan Pharmaceuticals Inc valsartan and hydrochlorothiazide 0378-6321
A-S Medication Solutions valsartan and hydrochlorothiazide 50090-5985
Northwind Pharmaceuticals LLC valsartan and hydrochlorothiazide 51655-243
Northwind Pharmaceuticals LLC valsartan and hydrochlorothiazide 51655-389
Preferred Pharmaceuticals Inc valsartan and hydrochlorothiazide 68788-7887
>Company >Ingredient >NDC

Subscribe to access the full database, or Sign Up

Excipient focus: TRISODIUM CITRATE DIHYDRATE

Excipient focus: VANILLIN

Excipient focus: WATER

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2024 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
 NCE-1 Patent Challenge Dates 2024 - 2025
 Trigger-based marketing for the life sciences
 Get DrugPatentWatch Business Intelligence Reports at Amazon.com
 DrugChatter - AI-based answers to questions about drugs
 RxJam - Digital Marketing for Life Sciences
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links

Follow DrugPatentWatch:

  DrugPatentWatch Linkedin Group